Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| APO-AMLODIPINE-ATORVASTATIN TABLETS 5MG/10MG | N/A | N/A | N/A | 6/27/2016 | |
| OLMESARTAN/AMLODIPINE SANDOZ TABLETS 20MG/5MG | N/A | N/A | N/A | 11/13/2024 | |
| AMLOVAS TAB 10MG | N/A | N/A | N/A | 10/5/2006 | |
| OLMESARTAN/AMLODIPINE SANDOZ TABLETS 40MG/5MG | N/A | N/A | N/A | 11/13/2024 | |
| WAMLOX TABLETS 10MG/160MG | N/A | N/A | N/A | 7/18/2022 | |
| AMLODIPINE/VALSARTAN TEVA TABLETS 5MG/80MG | N/A | N/A | N/A | 9/14/2021 | |
| WAMLOX TABLETS 5MG/160MG | N/A | N/A | N/A | 7/18/2022 | |
| CADUET TAB 10MG/80MG | N/A | N/A | N/A | 10/20/2005 | |
| AMLOPRES-10 TAB 10MG | N/A | N/A | N/A | 2/28/2003 | |
| AMLOVAS TAB 5MG | N/A | N/A | N/A | 9/11/2006 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.